Advertisement

Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Survival Benefit With Lenvima/Keytruda for Advanced Clear Cell RCC Continues After 4 Years

June 5th 2023

After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.

Lenvima Plus Keytruda ‘Stood the Test of Time’ for Kidney Cancer

June 5th 2023

Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.

Three-Drug Regimen Is Promising Across Kidney Cancer Subtypes

June 4th 2023

Cabometyx, Opdivo and Yervoy led to high disease control rates across different subgroups of patients with kidney cancer, research showed.

Welireg Plus Lenvima Has ‘Promising Antitumor Activity’ in Kidney Cancer Subset

June 4th 2023

Nearly three-fourths of patients with clear cell renal cell carcinoma had a disease response lasting 12 months or longer after being treated with Welireg and Lenvima, study data showed.

First Patient Dosed in Phase 1/2 Trial Assessing Novel Immunotherapy Alone, With Keytruda

April 12th 2023

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

Phase 3 Cabometyx Study in Patients with Kidney Cancer Fails to Meet Goal

March 10th 2023

Cabometyx plus Tecentriq failed to improve progression-free survival in patients with kidney cancer.

Lenvima-Keytruda Continues to Show Benefit in Advanced Kidney Cancer

February 28th 2023

The drug duo Lenvina plus Keytruda led to improved outcomes for patients with advanced renal cell carcinoma, extended follow-up of the CLEAR trial showed.

Ointment Being Studied for Hand-Foot Skin Reaction Related to Kidney Cancer Treatment

February 21st 2023

A clinical trial is currently enrolling patients who are experiencing hand-foot skin reaction as a result of kidney cancer treatment.

Adding Cabometyx to Immunotherapy Improves Kidney Cancer Outcomes

February 20th 2023

The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.

Genetic Targets Open the Door to New Treatment Options in Kidney Cancer

December 29th 2022

Discovering different genetic mutations to target ... continues to add to the excitement.

Running the Race of Cancer

December 28th 2022

Going through cancer is a marathon, not a sprint.

Becoming an Active Participant in Kidney Cancer Care

December 27th 2022

As a part of its “Speaking Out” video series, CURE® spoke with Meryl Uranga, on behalf of KidneyCAN, about the importance of working as a team with their clinicians and getting educated before making decisions.

The Silver Lining of Failure in Cancer Drug Development

December 26th 2022

One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.

Sarcomatoid Renal Cell Carcinoma: From Limited Options to a 'Game Changer'

December 23rd 2022

FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.

A Sea Change in Treatment for von Hippel-Lindau Disease

December 20th 2022

HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease.

Top Kidney Cancer Articles of 2022

December 19th 2022

Take a look at the top advancements and most popular articles about kidney cancer from the year 2022.

20 Years of Cancer Care Advancements

December 15th 2022

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

Welireg Made a von Hippel-Lindau Survivor Feel Like a 'Medical Miracle'

December 15th 2022

When Sean Korbitz was a 20-year-old college student, his life trajectory changed with a rare cancer diagnosis, resulting in the removal of 40 tumors; fifteen years later, a new drug made him feel like a “medical miracle.”

Risk Versus Reward: Managing Side Effects of Kidney Cancer Treatments

December 13th 2022

Newer drugs for kidney cancer have proven extremely effective but can cause unwanted symptoms that affect safety and quality of life.

‘Any Exercise Is Better Than No Exercise’ to Potentially Improve Mental Health in Patients With Kidney Cancer

December 5th 2022

A kidney cancer diagnosis may negatively affect a patient’s mental health; however, exercise may help put them at ease.

Integrative Care May Be Beneficial During Treatment for Kidney Cancer

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about integrative care for kidney cancer.

Speaking Out About Side Effects From Kidney Cancer Treatment

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga, a patient advocate, about the side effects associated with kidney cancer treatment.

Patients Should Stay Educated on the Growing Treatment Options for Kidney Cancer

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.

Setting Expectations in a Patient-Physician Relationship Following a Kidney Cancer Diagnosis

November 7th 2022

As a part of its Speaking Out video series, on behalf of KidneyCAN, CURE® spoke with Meryl Uranga about the importance of patients being their own advocate when communicating with their physician.

My 6 Rules for Navigating Cancer and Medical Misdiagnoses

October 31st 2022

I was misdiagnosed twice before receiving my kidney cancer diagnosis, and along the way, I learned the importance of expert doctors and clinical trials.

The Past 20 Years Have Been Revolutionary for Kidney Cancer

October 19th 2022

Once seen as a malignancy resistant to typical treatments such as chemotherapy, metastatic kidney cancer has come a long way in the past 20 years.

The Last 20 Years of Advancements Were 'Revolutionary' for Metastatic Kidney Cancer Treatment

October 12th 2022

Twenty years of FDA approvals for the treatment of metastatic kidney cancer have allowed patients to live longer.

FDA Approves Avastin Biosimilar to Treat Six Diseases Including Certain Colon, Lung, Kidney Cancers

September 28th 2022

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

Telaglenastat-Cabometyx Combination May Not Improve Survival in Pretreated Kidney Cancer Compared With Cabometyx Alone

September 20th 2022

Although patients treated with the combination did not have significant improvements in survival, telaglenastat and Cabometyx did not increase the rate of side effects in patients.

Adding Cabometyx to Immunotherapy Combination Improves Outcomes for Advanced Kidney Cancer

September 12th 2022

The addition of Cabometyx to the current standard-of-care frontline regimen of Opdivo plus Yervoy improved progression-free survival outcomes in patients with advanced kidney cancer.

NEXT PAGE
PREVIOUS PAGE
Advertisement
Advertisement